These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31817815)

  • 21. Initial Real-World Practical Experience of Sacubitril/Valsartan Treatment in Japanese Patients With Chronic Heart Failure.
    Nakamura M; Imamura T; Joho S; Kinugawa K
    Circ Rep; 2021 Oct; 3(10):589-593. PubMed ID: 34703936
    [No Abstract]   [Full Text] [Related]  

  • 22. Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data.
    Cuthbert JJ; Pellicori P; Clark AL
    Ther Clin Risk Manag; 2020; 16():715-726. PubMed ID: 32848403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty.
    Cacciatore F; Amarelli C; Maiello C; Mattucci I; Salerno G; Di Maio M; Palmieri V; Curcio F; Pirozzi F; Mercurio V; Benincasa G; Golino P; Bonaduce D; Napoli C; Abete P
    ESC Heart Fail; 2020 Apr; 7(2):757-762. PubMed ID: 32074411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction.
    Vitale G; Romano G; Di Franco A; Caccamo G; Nugara C; Ajello L; Storniolo S; Sarullo S; Agnese V; Giallauria F; Novo G; Clemenza F; Sarullo FM
    J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30791533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study).
    Di Lenarda A; Di Gesaro G; Sarullo FM; Miani D; Driussi M; Correale M; Bilato C; Passantino A; Carluccio E; Villani A; Degli Esposti L; d'Agostino C; Peruzzi E; Poli S; Iacoviello M
    J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Sacubitril/Valsartan on surfactant binding proteins, central sleep apneas, lung function tests and heart failure biomarkers: Hemodynamic or pleiotropism?
    Mapelli M; Mattavelli I; Salvioni E; Banfi C; Ghilardi S; De Martino F; Gugliandolo P; Mantegazza V; Volpato V; Basile C; Branco Pires MIF; Sassi V; Nusca B; Vignati C; Contini M; Sforza C; Biondi ML; Perrone Filardi P; Agostoni P
    Front Cardiovasc Med; 2022; 9():971108. PubMed ID: 36186983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.
    Januzzi JL; Packer M; Claggett B; Liu J; Shah AM; Zile MR; Pieske B; Voors A; Gandhi PU; Prescott MF; Shi V; Lefkowitz MP; McMurray JJV; Solomon SD
    Circ Heart Fail; 2018 Oct; 11(10):e005133. PubMed ID: 30354399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF.
    Selvaraj S; Claggett B; Pozzi A; McMurray JJV; Jhund PS; Packer M; Desai AS; Lewis EF; Vaduganathan M; Lefkowitz MP; Rouleau JL; Shi VC; Zile MR; Swedberg K; Solomon SD
    Circulation; 2019 Oct; 140(17):1369-1379. PubMed ID: 31510768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.
    Katsanos S; Bistola V; Parissis JT
    Expert Rev Clin Pharmacol; 2016 Apr; 9(4):513-523. PubMed ID: 26873036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Left Ventricular Ejection Fraction and N-Terminal pro-B-type Natriuretic Peptide after Sacubitril/Valsartan for Predicting Outcomes in Patients with Heart Failure with Reduced Ejection Fraction.
    Fang CC; Jao YTFN
    Acta Cardiol Sin; 2023 Mar; 39(2):297-308. PubMed ID: 36911550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease-A Real-World Experience.
    Pereira SC; Rodrigues T; Nunes-Ferreira A; Agostinho JR; Pinto FJ; Brito D
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coronary Flow Reserve Changes after Angiotensin Receptor-Neprilysin Inhibitor Treatment in Heart Failure with Reduced Ejection Fraction.
    Karaayvaz EB; Güz G
    Acta Cardiol Sin; 2023 Nov; 39(6):871-878. PubMed ID: 38022415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of B-type natriuretic peptide and N-terminal pro-brain natriuretic peptide during acute decompensated heart failure in a chronic heart failure patient with reduced ejection fraction treated with Sacubitril/Valsartan: a case report.
    Tiepolo A; Nougué H; Damoisel C; Launay JM; Vodovar N; Mebazaa A
    Eur Heart J Case Rep; 2019 Sep; 3(3):ytz108. PubMed ID: 31660484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Add-on Sacubitril/Valsartan Therapy Induces Left Ventricular Remodeling in Non-responders to Cardiac Resynchronization Therapy to a Similar Extent as in Heart Failure Patients Without Resynchronization.
    Szabó KM; Tóth A; Nagy L; Rácz V; Pólik Z; Hodosi K; Nagy AC; Barta J; Borbély A; Csanádi Z
    Cardiol Ther; 2024 Mar; 13(1):149-161. PubMed ID: 38216822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea.
    Pelaia C; Armentaro G; Volpentesta M; Mancuso L; Miceli S; Caroleo B; Perticone M; Maio R; Arturi F; Imbalzano E; Andreozzi F; Perticone F; Sesti G; Sciacqua A
    Front Cardiovasc Med; 2022; 9():861663. PubMed ID: 35449875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients.
    Valentim Goncalves A; Pereira-da-Silva T; Galrinho A; Rio P; Moura Branco L; Soares R; Ilhao Moreira R; Cruz Ferreira R
    Am J Cardiovasc Dis; 2020; 10(3):174-181. PubMed ID: 32923098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study.
    Armentaro G; D'Arrigo G; Miceli S; Cassano V; Perticone M; Maio R; Marra AM; Arturi F; Cittadini A; Tripepi G; Sesti G; Sciacqua A
    Front Physiol; 2022; 13():897109. PubMed ID: 35694400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction.
    Zhao Y; Tian LG; Zhang LX; Ma T; Di L; Wang YB; Gu XS; Wang DD; Gao S; Wang H
    Pulm Circ; 2022 Jul; 12(3):e12034. PubMed ID: 35874853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does Speckle Tracking Transthoracic Echocardiography Indicate Subtle Changes in Left Ventricular Function in Heart Failure Patients with Reduced Ejection Fraction Treated by Sacubitril-valsartan?
    Setouhi A; Mohamed ON; Farrag HMA; Taha NM; Ramadan A; Askalany HT
    J Cardiovasc Echogr; 2024; 34(1):19-24. PubMed ID: 38818314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator.
    Russo V; Bottino R; Rago A; Papa AA; Liccardo B; Proietti R; Manna V; Golino P; D'Onofrio A; Nigro G
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32294983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.